

To: (10)(2e) <(10)(2e)> @rivm.nl]
From: (10)(2e)
Sent: Wed 7/15/2020 10:51:25 AM
Subject: FW: Euro Surveillance test performance paper - Final review round, due by Fri 17 July
Received: Wed 7/15/2020 10:51:25 AM
[Performance paper.docx](#)
[For reference only.docx](#)
[Performance paper - Supplementary Tables.xlsx](#)

Gewoon doorsturen en vragen of ze zelf rechtstreeks aan ECDC willen antwoorden. Als ze weten dat directe collega's op vakantie zijn vragen of ze daarmee contact kunnen opnemen of voor hun kunnen antwoorden.

Grtz (10)(2e)

From: (10)(2e) <(10)(2e)> @ecdc.europa.eu>
Sent: woensdag 15 juli 2020 10:06
To: (10)(2e) <(10)(2e)> @rivm.nl>; (10)(2e) <(10)(2e)> @rivm.nl>
Cc: (10)(2e) <(10)(2e)> @ecdc.europa.eu>
Subject: RE: Euro Surveillance test performance paper - Final review round, due by Fri 17 July

Dear (10)(2e)

Can you forward this to the Dutch co-authors as before and forward back their replies? Please let me know if you want to discuss any issues on how best to handle this review round, I know it is short notice and I hope there will not be issues with that.

Kind regards,

(10)(2e)



(10)(2e)
 PhD
 Expert Public Health Bioinformatics
 Surveillance, PHF
 Phone +46 (10)(2e)
 (10)(2e) @ecdc.europa.eu

**European Centre for
 Disease Prevention and Control (ECDC)**
 Gustav III:s boulevard 40, 169 73 Solna, Sweden
 Phone +46 (10)(2e)
www.ecdc.europa.eu

Follow ECDC on:



From: (10)(2e) <(10)(2e)> @ecdc.europa.eu>
Sent: 15 July 2020 10:01
To: (10)(2e) @itg.be; (10)(2e) @uzleuven.be; (10)(2e) @uzleuven.be; (10)(2e) @mphs.moh.gov.cy;
 (10)(2e) @thl.fi; (10)(2e) @thl.fi; (10)(2e) @thl.fi; (10)(2e) @thl.fi; (10)(2e) @chu-lyon.fr; (10)(2e) @pasteur.gr;
 (10)(2e) @pasteur.gr; (10)(2e) ((10)(2e) @bfm.hr) <(10)(2e) @bfm.hr>; (10)(2e) @ins.etat.lu;
 (10)(2e) @ins.etat.lu; (10)(2e) @ins.etat.lu; (10)(2e) @rivm.nl; (10)(2e) @rivm.nl;
 (10)(2e) @wihe.pulawy.pl; (10)(2e) @wsse.waw.pl; (10)(2e) @interia.eu; (10)(2e) @wsse.waw.pl;
 (10)(2e) @gmail.com; (10)(2e) @pzh.gov.pl; (10)(2e) @pzh.gov.pl; (10)(2e) @pzh.gov.pl; (10)(2e) @insa.min-
 saude.pt; (10)(2e) @insa.min-saude.pt; (10)(2e) @insa.min-saude.pt; (10)(2e) @sll.se; (10)(2e) @sll.se;
 (10)(2e) @nlzoh.si; (10)(2e) @nlzoh.si
Cc: (10)(2e) <(10)(2e)> @ecdc.europa.eu>; (10)(2e) <(10)(2e)> @ecdc.europa.eu>; (10)(2e)
 <(10)(2e)> @ecdc.europa.eu>; PHE Support.Microbiology <(10)(2e)> @ecdc.europa.eu>
Subject: Euro Surveillance test performance paper - Final review round, due by Fri 17 July

Dear co-authors,

After incorporating your comments on the second review round early July, the paper is now ready for its third and final review round **by Friday 17 July EOB**. Our apologies for the short notice, but we want to avoid issues with people going on holiday and in this third round no major issues are expected anymore.

The following main changes have been done:

- The author list has been finalised and all remaining authors have contributed and verified their data.
- All 117 papers from the systematic review have now been assessed and their data included. Substantially more detail was added on how papers were selected. A verification round performed by ECDC on this assessment is in progress and will be finalised in parallel with this review round. This may result in some changes but unlikely in any conclusions.
- The total number of index test results (contributed by you/from public sources) is currently 39439 (13919/25520) for reference test positive samples (sensitivity panel), and 45804 (14934/30870) for reference test negative samples (specificity panel). With the current exclusions for sensitivity and specificity panels for the public sources, pending verification and before further exclusion based on ≤ 10 dpo for Ab tests, this drops to around 83% and 90% of the total.
- Supplementary tables 2 and 3, i.e. the study list and all performance results are included. These contain the unpublished data from all co-authors and may not be shared with other people.
- References were added.

Attached you will find the paper to review, with all non-contentious tracked changes accepted and corresponding (green) comments removed. Only tracked changes and (yellow) comments that are likely to require further review are included. As before, a version with all tracked changes and comments is attached as well for reference.

You should do the following:

- Review the paper a final time, with particular emphasis on yellow comments and tracked changes. All changes should be tracked.
- **Add your consent for submitting the paper preferably now already**, in the last column of the author table at the beginning of the document, to avoid delays due to holidays. This can be done after review round 3 as well in particular if you think important points need to be addressed first, but please let us know if you will be unavailable in the near future. If one of your direct colleagues is on leave at present and not back before 20 July, please try to contact them if possible for this consent or provide it on their behalf if you think this is ok.
- If not done yet, add your **CRedit** (Contributor Roles Taxonomy) statement in the author table at the beginning. A default (investigation, data curation, writing-review) has been put in place for now and will be considered final unless changed. Some tracked changes were also made to existing statements to ensure consistency across authors and using the CRedit terminology.
- If not done yet, add any funding and declaration of interest.
- Add any references you think are appropriate, at least one still needs to be added.
- Verify at least one aggregated sensitivity and specificity result from supplementary Table S3 for correctness. Choose one for which at least two studies were used. If you find an issue, please reply to me asap. The supplementary tables are inside an Excel file embedded into the Word document, and attached as well.

After this review round, comments will be incorporated as before and the paper will be sent for internal clearance at ECDC as per our procedures. We will keep you up to date on the progress with that. In the meantime, please do not hesitate to contact me if there are immediate issues.

Kind regards,

(10)(2e)

(10)(2e)
PhD
Expert Public Health Bioinformatics
Surveillance, PHF
Room number (10)(2e)



Confidentiality Notice
If you are not the intended recipient of this message, you are hereby kindly requested, to, consecutively, refrain from disclosing its content to any third party, delete it, and inform its sender of the erroneous transmittal.